| Title |
Ten Developments in the Use of Biologicals for Systemic Lupus Erythematosus
|
|---|---|
| Published in |
Current Rheumatology Reports, May 2013
|
| DOI | 10.1007/s11926-013-0337-z |
| Pubmed ID | |
| Authors |
Daniel J. Wallace |
| Abstract |
Belimumab has recently been approved, and several other types of biological therapy with different mechanisms of action are currently in phase II and III studies. This review puts these approaches in context, emphasizing mechanistic categories and clinical trial designs. Most of the promising approaches involve B cell depletion or modulation. Post-approval experience with belimumab is critically reviewed. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 20 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 30% |
| Lecturer | 2 | 10% |
| Other | 2 | 10% |
| Student > Bachelor | 2 | 10% |
| Professor | 2 | 10% |
| Other | 3 | 15% |
| Unknown | 3 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 60% |
| Chemistry | 2 | 10% |
| Immunology and Microbiology | 1 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Materials Science | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 3 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 June 2013.
All research outputs
#18,341,369
of 22,713,403 outputs
Outputs from Current Rheumatology Reports
#550
of 706 outputs
Outputs of similar age
#145,477
of 193,512 outputs
Outputs of similar age from Current Rheumatology Reports
#6
of 10 outputs
Altmetric has tracked 22,713,403 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 706 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 193,512 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.